CHMP Recommends Caprelsa Approval in EU on Condition AstraZeneca Conducts PGx Trial | GenomeWeb

Originally published Nov. 29.

By Turna Ray

Following a conditional recommendation from the European Commission's Committee for Medicinal Products for Human Use, AstraZeneca has decided to conduct additional pharmacogenomic investigations of its drug Caprelsa to ensure that medullary thyroid cancer patients with unknown or negative RET mutations derive benefit from the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.